Five highlights of the pharmaceutical industry in 2017
Release time:
2020-08-14
2017 NPC and CPPCC Five Major Points in Pharmaceutical Industry
3# September 3 , 2017 NPC and CPPCC will be held in Beijing. The issues and decisions of the NPC and CPPCC will directly affect the overall trends and trends of the industry in the following year and have a profound impact on the future economy and major assets. The following is a summary of the highlights of 5 in the pharmaceutical industry during the 2017 NPC and CPPCC sessions.
1 , Supply-side Reform: Value Chain Distribution Faces Reconstruction
The so-called supply-side reform is to promote the development of economic industry by liberating productivity from the supply and production sides. As early as last year's Spring Festival, the State Council meeting focused on the pharmaceutical industry and proposed measures such as "aiming at the urgent needs of the masses, improving the safety evaluation and product traceability system, combining the" three medical "linkage reform, and building a pharmaceutical circulation network throughout the township", hoping to promote the innovation and upgrading of the pharmaceutical industry through supply-side reform. From
to this year, the health planning Commission held a press conference on 2 8 , saying that through the implementation of the "action plan to further improve medical services", the service process has been continuously optimized, the medical quality has been continuously improved, the service mode has been continuously innovated, and the doctor-patient relationship has been continuously harmonious. 2017 The Health Planning Commission and the State Administration of Traditional Chinese Medicine have identified 11 key tasks to further improve medical services, including expanding the real-name appointment diagnosis and treatment pilot.
In addition, the General Office of the State Council issued a blockbuster document entitled "Several Opinions on Further Reforming and Improving Drug Production, Circulation and Use Policies" on 2 January 9 , which aroused strong repercussions in the pharmaceutical industry. The "opinion" points out that starting from the three major links of drug production, circulation and use is an important reform document covering the entire pharmaceutical industry chain, which will play a key role in further promoting the supply-side structural reform of the pharmaceutical industry. it will also have a far-reaching impact on the future healthy development of the pharmaceutical industry.
If 2016 is the year of supply-side reform, then 2017 will be the year of deepening the supply-side reform of medical reform. Supply-side structural reform has become the key word of this year's "two sessions" medicine.
2 , medical reform: the formation of a basic medical and health system framework
medical reform has always been a hot issue of concern. the key work points of 2017 published by the health planning Commission proposed that the medical reform should be continuously deepened and the formation of a basic medical and health system framework should be accelerated. These include measures such as promoting the hierarchical diagnosis and treatment system, accelerating the establishment of a modern hospital management system, and implementing the reform of the drug supply guarantee system. In addition, medical reform has also been mentioned in the government work reports of the local two sessions that have been implemented, and various localities have "bright moves" to solve the problem of people seeing a doctor ".
Zhejiang Province has achieved "double sinking and two upgrading" of medical resources through the establishment of a medical consortium, alleviating the current situation of people's difficulty in seeing a doctor, and accelerating the reform of "Internet + medical prices.
medical reform has always been one of the key reform projects promoted by the State Council. Deepening the reform of the medical and health system and strengthening the construction of the medical service system will become the focus of attention and heated discussion among the representatives of the two sessions.
3 , medical and nursing integration: make up for shortcomings and solve the pension problem
With the increasing aging of the population, new requirements have been put forward for the development of medical care. In the "Several Opinions on Accelerating the Development of Elderly Care Services" issued by the State Council in 2013 , it was proposed to "promote the integrated development of medical care and elderly care", which pointed out the direction for the development of my country's elderly care industry. This year, Zhejiang proposed to actively promote the reform of the old-age insurance system, study and formulate a linkage adjustment mechanism for the basic pension for retirees and the minimum standard of basic pension for urban and rural residents, and steadily raise the standards of basic pension and basic pension.
At the National Two Sessions, elderly care has become an issue of high concern, and the quality of life of the elderly in their later years will affect the stability of the entire society. How to improve the quality of elderly care services has received special attention.
4
, Pollution Control: Hundreds of pharmaceutical companies may face suspension of production. Environmental protection has always been a topic of close attention throughout the country. According to the data of the legal network voting system, as of 2017
2 April 28 , smog control ranked among the top 10 hot spots of the NPC and CPPCC with 19598 votes. 2017 is the second year of the 13th Five-Year Plan and a key year for environmental protection. Last year in the middle and late of December 1, there was a large-scale continuous severe air pollution in our country. Satellite monitoring shows that the scope of smog was once expanded to 17
provinces, autonomous regions and municipalities in, covering an area of 142 .09 million square kilometers, that is to say, more than 1/7 of the country was shrouded in smog. With such a "power" of the haze, naturally become the focus of attention of the various provinces. It is no longer news to use ten "haze" volts to describe the weather in Beijing-Tianjin-Hebei region during winter heating. However, after the Spring Festival this year, the "Beijing-Tianjin-Hebei and Surrounding Areas Air Pollution Prevention and Control Work Plan for 2017
(Draft for Comments ) " ( hereinafter referred to as "Plan" ) once again pushed pharmaceutical companies in the region to the forefront. If this "plan" becomes a reality, hundreds of pharmaceutical enterprises in "2+26 " cities such as Beijing, Tianjin, Shijiazhuang, Jinan, Zhengzhou and Taiyuan will not be allowed to produce for 120 days throughout the year. According to the implementation promotion plan of ( Ten Atmospheric Articles
)issued by the State Council in 2013 , 2017 is the final assessment year of the action plan. Environmental protection has naturally become one of the hot words of the two sessions this year.
, Reform of State-owned Enterprises: Mixed Reform of Pharmaceutical Enterprises Station in UpportSince 2016
, various regions have successively issued a number of special supporting documents to implement the "Guiding Opinions on Deepening the Reform of State-owned Enterprises" promulgated and implemented by the CPC Central Committee and the State Council, and the "four beams and eight pillars" of the reform of state-owned enterprises have risen, accelerate from "design" to "construction".1 Since September, the local two sessions have been intensively held, and the reform of state-owned enterprises has once again become the focus of the local "two sessions. 2016
# Decemberth June 29 , Yunnan Baiyao controlling shareholder Baiyao Holdings introduced about 254 billion yuan to Xinhuadu Industrial Group Co., Ltd. through capital increase. Baiyao Holding's equity structure was changed to Yunnan SASAC and Xinhuadu each holding 50% equity. At present, the company's core business consists of the provincial pharmaceutical company, the pharmaceutical division, the health products division and the traditional Chinese medicine resources division, which are respectively responsible for the four major business sectors of pharmaceuticals, health daily chemical products, traditional Chinese medicine resources products and pharmaceutical commerce. The initial completion of the mixed reform plan of Baiyao Holdings has made Yunnan Baiyao a model of performance growth in the pharmaceutical industry. Since the listing of in 1993 , Yunnan Baiyao has led its peers in performance growth. Compared with listed companies under state-owned enterprises in Yunnan Province, Yunnan Baiyao's return on net assets and other indicators are also far ahead. In the report on accelerating the reform of state-owned enterprises recently released by the Tianjin State-owned Assets Supervision and Administration Commission, the timetable and roadmap for Tianjin Pharmaceutical Group Co., Ltd. to promote the reform of state-owned enterprises clearly emerged. Among them, increasing the intensity of mixed reform, using the listing platform to achieve asset securitization and improving the assessment and incentive mechanism have become the three highlights. Some pharmaceutical industry analysts pointed out that from the perspective of the reform route, Tianyao Group has continued the overall thinking of the current state-owned enterprise reform. It is another typical case of initiating the reform of state-owned enterprises in the pharmaceutical industry after Yunnan Baiyao.
pharmaceutical enterprise reform results show, the company's profitability and overall value has been further improved. On the basis that the top-level design of the reform of state-owned enterprises has been basically completed, the reform of pharmaceutical state-owned enterprises will gradually reach a climax in 2017
, which will affect the future direction of pharmaceutical investment to a certain extent. (article from the network)
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31